The in-vitro diagnostics (IVD) market in Saudi Arabia is projected to grow at a compound annual growth rate (CAGR) of 6.01% from 2023 to 2030, expanding from USD 2.78 billion in 2022 to USD 4.44 billion by 2030. This growth is largely driven by efforts to enhance the country’s healthcare sector.
IVD refers to medical devices and reagents used for diagnostic tests on biological samples such as blood, urine, and tissues. These tests help in detecting infectious diseases, autoimmune disorders, and other medical conditions, as well as monitoring drug therapy.
The market has been experiencing steady growth, supported by increased awareness of early disease detection, a rising prevalence of chronic and infectious diseases, and advancements in medical technology. Government initiatives and private sector investments to strengthen Saudi Arabia’s healthcare infrastructure further contribute to market expansion.
A growing elderly population and lifestyle changes have also heightened the demand for fast and accurate diagnostic solutions. Key IVD market segments—including clinical chemistry, immunoassays, molecular diagnostics, hematology, and point-of-care testing—are seeing significant growth. In particular, molecular diagnostics and genetic testing are gaining traction due to their role in early disease identification and personalized treatment.
Companies operating in the market, both multinational corporations and local manufacturers, are actively innovating to meet evolving healthcare needs. Regulatory bodies such as the Saudi Food and Drug Authority (SFDA) play a crucial role in ensuring product quality and safety.
Click – https://www.marketsandata.com/industry-reports/saudi-arabia-in-vitro-diagnostics-market
Key Developments in the Market
Advancements in Immunodiagnostics
Immunodiagnostics has seen remarkable progress, with new technologies and an increased focus on healthcare driving innovation. Automated systems such as chemiluminescence and ELISA platforms have improved the accuracy and efficiency of diagnostic tests, enabling quicker disease detection. The use of novel biomarkers and monoclonal antibodies has also enhanced diagnostic capabilities, leading to early disease identification and personalized treatments.
For example, in December 2022, bioMĂ©rieux received CE-marking for its VIDAS KUBE automated immunoassay system. This technology, used in over 160 countries, has revolutionized immunoassays by providing laboratories with simple, automated, and reliable diagnostic solutions.
High Prevalence of Chronic Diseases Driving Market Demand
The increasing incidence of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases is a key driver of the IVD market in Saudi Arabia. These conditions require reliable diagnostic tools for timely detection and monitoring. According to the International Diabetes Federation (IDF), the number of diabetes cases in Saudi Arabia is expected to rise from 4.3 million in 2021 to 7.5 million by 2045.
Similarly, the World Health Organization (WHO) reported in September 2023 that noncommunicable diseases (NCDs) account for 74% of all global deaths, with cardiovascular diseases being the leading cause, followed by cancer, respiratory diseases, and diabetes. The growing burden of these diseases is accelerating the demand for in-vitro diagnostic solutions.
Strategic Collaborations to Drive Innovation
Partnerships among healthcare institutions, research organizations, regulatory authorities, and industry leaders are crucial for advancing the IVD market in Saudi Arabia. These collaborations facilitate knowledge exchange, resource-sharing, and regulatory streamlining, leading to the development of innovative diagnostic technologies.
For instance, in April 2023, Oxford Nanopore Technologies partnered with bioMĂ©rieux to advance the use of nanopore sequencing in infectious disease diagnostics, aiming to improve global healthcare outcomes.
Market Segments and Future Trends
Immunodiagnostics Leading, Molecular Diagnostics Growing Rapidly
The immunodiagnostics segment dominates the market, holding a 35.14% share, while molecular diagnostics is the fastest-growing segment, expected to expand at a CAGR of 7.19% during the forecast period. The demand for immunodiagnostics is driven by the rise in infectious and immunological diseases, whereas the prevalence of genetic disorders—partly due to consanguineous marriages—is fueling the need for molecular diagnostics.
Heavy Dependence on Imports for IVD Products
Despite its rapid development, Saudi Arabia relies heavily on imports for its healthcare needs, with over 70% of medical devices and diagnostic tools sourced from Europe, Asia, and the United States. According to the Gulf Cooperation Council (GCC), the healthcare sector in the region generates 70% of its revenue from medical devices, 19% from in-vitro diagnostics, and 11% from medical imaging.
To reduce reliance on imports, Saudi Arabia launched the Vision 2030 initiative, aimed at improving healthcare access, modernizing medical infrastructure, and encouraging private sector investment in domestic production. This initiative presents significant opportunities for manufacturers looking to establish local production facilities.
Impact of COVID-19 on the Market
During the early stages of the COVID-19 pandemic, Saudi Arabia implemented lockdowns, restricted international trade, and imposed travel bans, initially leading to a decline in medical diagnoses. However, as cases surged, demand for diagnostic testing increased across hospitals, clinics, and mobile units, driving the need for IVD solutions.
Recognizing this opportunity, in June 2021, G42 Healthcare and Seegene Inc. signed a Memorandum of Understanding (MoU) to deploy mobile diagnostic and testing laboratories in Saudi Arabia and other Middle Eastern countries, helping to meet the rising demand for diagnostic services.
Future Market Outlook (2023 – 2030)
- Growing chronic disease prevalence and genetic disorders will continue to drive demand for IVD solutions.
- Technological advancements in diagnostic tools and instruments will support market expansion.
- The molecular diagnostics segment will experience the fastest growth, driven by the increasing need for genetic testing.
- Point-of-care diagnostics will gain traction as demand for personalized treatment and rapid testing rises.
Conclusion
Saudi Arabia’s in-vitro diagnostics market is poised for steady growth, driven by an increasing burden of chronic diseases, advancements in diagnostic technologies, and strategic collaborations between key industry players. While the country still relies heavily on imports, government initiatives such as Vision 2030 present significant opportunities for local production and market expansion. The continued evolution of immunodiagnostics, molecular diagnostics, and point-of-care testing will further shape the future of the IVD industry in the region.
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343–3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
According to the Renub Research report, Saudi Arabia In Vitro Diagnostics Market is expected to reach US$ 1,400.92 Million by 2027.There has been stable growth in the adoption of IVD in Saudi Arabia.
Some of the other factors catalysing the growth of IVD in Saudi Arabia include rising healthcare expenditures, improving healthcare infrastructure, initiatives by the government, rising awareness levels, etc.
Looking forward, Renub Research expects the Saudi Arabia IVD Industry to exhibit growth with a CAGR of 7.10% during 2020-2027.By Segments – Immunochemistry is driving the Saudi Arabia IVD Market.
Furthermore, the ongoing development of government healthcare infrastructure is anticipated to enhance the existing hospital facilities.
Thus, the demand for Government Hospitals & Laboratory-based IVD tests is increasing.The market for IVD in Saudi Arabia is moderately competitive, and major players are actively present in the country, promoting high product availability in Saudi Arabia.
Among the top companies operating in the In-Vitro Diagnostics in Saudi Arabia, Roche, Abbott, Siemens Healthineers, Sysmex Corporation, and Danaher Corporation has been studied thoroughly in the report.Renub Research report titled “Saudi Arabia In Vitro Diagnostics (IVD) Market, by Segments [Immunochemistry, Clinical Chemistry, Hematology, Hemostasis, Microbiology, Molecular Diagnostic, Self Monitoring of Blood Glucose (SMBG) and Point of Care Testing (POCT)]; by Applications (Infectious Diseases, Cardiovascular Diseases, Oncology, Diabetes and others); By End User (Government Labs & Hospitals, Private Labs & Hospitals and others) and by Companies (Roche, Abbott, Siemens Healthineers, Sysmex Corporation and Danaher Corporation)” provides a complete analysis of Saudi Arabia In-Vitro Diagnostics (IVD) Market.Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/saudi-arabia-in-vitro-diagnostics-market-p.phpSegments – Market have been covered from 8 viewpoints1.
